HIV Treatment Clinical Brief: Dolutegravir

Published Thursday, January 11, 2018

Dolutegravir (DTG) is a well-tolerated antiretroviral that is effective at suppressing HIV, can be taken once a day, and has a high barrier to resistance. It is increasingly recognized as a potential first-line treatment option for HIV. DTG belongs to the class of antiretroviral medicines called integrase inhibitors (INIs) or integrase strand transfer inhibitors (INSTIs). Integrase inhibitors work by blocking integrase, the enzyme required for HIV to insert its viral DNA into the DNA of a host CD4 cell.

This clinical brief provides guidance on the use of DTG in varying adult and pediatric populations. It is available in EnglishBahasa IndonesiaChinese MandarinJapaneseKhmerKoreanMalayThai, and Vietnamese.